Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings

BMC Health Services Research

Volumn 10, Issue SUPPL. 1, 2010, Pages

  Leisegang, Rory ^a   Maartens, Gary ^a   Hislop, Michael ^b   Regensberg, Leon ^b   Cleary, Susan ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Medscheme Pty Ltd   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

AFRICA; ARTICLE; DRUG COST; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; MORTALITY; ORGANIZATION AND MANAGEMENT; PATIENT COMPLIANCE; PROBABILITY; PROPORTIONAL HAZARDS MODEL; STATISTICS;

AFRICA, SOUTHERN; ANTI-RETROVIRAL AGENTS; DIRECT SERVICE COSTS; DRUG COSTS; EVIDENCE-BASED MEDICINE; HEALTH PLAN IMPLEMENTATION; HIV INFECTIONS; HUMANS; LIFE EXPECTANCY; MARKOV CHAINS; MEDICATION ADHERENCE; PRIVATE SECTOR; PROPORTIONAL HAZARDS MODELS;

EID: 77954338877     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-10-S1-S3     Document Type: Article

References (28)

1. Affordability - the forgotten criterion in health care priority setting. SM Cleary D McIntyre, Health Economics 2009 18 4 373 375 10.1002/hec.1450 19267322
2. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access: guidelines for a public health approach. WHO, Geneva: World Health Organization 2006
3. Markov models in medical decision making: a practical guide. FA Sonnenberg JR Beck, Medical Decision Making 1993 13 4 322 338 10.1177/0272989X9301300409 8246705
4. An Introduction to Markov Modelling for Economic Evaluation. A Briggs M Sculpher, Pharmacoeconomics 1998 13 4 397 409 10.2165/00019053-199813040-00003 10178664
5. Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting. S Cleary G Mooney D McIntyre, Health Econ 2009 DOI: 10.1002/hec.1542
6. Assessing efficiency and the costs of scaling-up HIV-treatment. SM Cleary D McIntyre AM Boulle, AIDS 2008 22 Suppl 1 35 S42 10.1097/01.aids.0000327621. 24232.71 18664951
7. National Antiretroviral Treatment Guidelines. Pretoria: National Department of Health 2004
8. Health Department approves new HIV treatment guidelines. A Thom, Health-e 2010
9. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Steiner A Prochazka, Journal of Clinical Epidemiology 1997 50 105 116 10.1016/S0895-4356(96)00268-5 9048695
10. A general method of compliance assessment using centralized pharmacy records: description and validation. J Steiner T Koepsell S Fihn T Inui, Med Care 1988 26 814 823 10.1097/00005650-198808000-00007 3398608
11. Adherence to triple therapy and viral load response 2000. S Low-Beer B Yip M O'Shaughnessy R Hogg J Montaner, JAIDS 2000 23 360 361 10836763
12. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. P Harrigan R Hogg W Dong B Yip B Wynhoven J Woodward,, et al. Journal of Infectious Diseases 2005 191 339 347 10.1086/427192 15633092
13. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Nachega M Hislop D Dowdy M Lo S Omer L Regensberg R Chaisson G Maartens, JAIDS 2006 43 78 84 16878045
14. Association of Antiretroviral Therapy Adherence and Health Care Costs. JB Nachega R Leisegang D Bishai H Nguyen M Hislop S Cleary L Regensberg G Maartens, Annals of Internal Medicine 2010 152 Mar 18 25 20048268
15. Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis. R Leisegang S Cleary M Hislop A Davidse L Regensberg F Little G Maartens, PloS Medicine 2009 6 12 e1000189. doi:1000110.1001371/journal.pmed.1000189. 10.1371/journal.pmed.1000189 19956658
16. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. L Ivers D Kendrick K Doucette, Clinical Infectious Diseases 2005 41 2 217 224 10.1086/431199 15983918
17. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. M Brinkhof F Dabis L Myer, Bulletin of the World Health Organization 2008 86 7 559 567 10.2471/BLT.07.044248 18670668
18. Historical CPIX key indicators. Statistics South Africa, STATSSA 2009
19. Federal Reserve Statistical Release: Foreign Exchange Rates (Annual). http://www.federalreserve.gov/releases/g5a/
20. How should cost data in pragmatic randomised trials be analysed? S Thompson J Barber, British Medical Journal 2000 320 7243 1197 1200 10.1136/bmj.320.7243.1197 10784550
21. A comparison of multivariable regression models to analyse cost data. S Dodd A Bassi K Bodger P Williamson, Journal of Evaluation in Clinical Practice 2006 12 1 76 86 10.1111/j.1365-2753.2006.00610.x 16422782
22. The cost-effectiveness of Antiretroviral Treatment in Khayelitsha, South Africa: a primary data analysis. SM Cleary D McIntyre AM Boulle, Cost Eff Resourc Alloc 2006 4 20 10.1186/1478-7547-4-20 (Pubitemid 46189708)
23. When to initiate HAART in sub-Saharan Africa? A South African cost-effectiveness study. M Badri S Cleary G Maartens J Pitt L-G Bekker C Orrell R Wood, Antiviral Therapy 2006 11 63 72 16518961
24. Effectiveness and cost effectiveness of early and late prevention on HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults. M Bachman, AIDS Care 2006 18 2 109 120 10.1080/09540120500159334 16338768
25. Cost-Effectiveness of HIV Treatment in Resource-Poor Settings - The Case of Cote d'Ivoire. S Goldie Y Yazdanpanah E Losina M Weinstein X Anglaret R Walensky H Hsu A Kimmel C Holmes J Kaplan,, et al. New England Journal of Medicine 2006 355 11 1141 1153 10.1056/NEJMsa060247 16971720
26. Cost-Effectiveness of Alternative Strategies for Initiating and Monitoring Highly Active Antiretroviral Therapy in the Developing World. A Vijayaraghavan M Efrusy P Mazonson O Ebrahim I Sanne C Santas, JAIDS 2007 46 1 91 100 17621241
27. The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda. E Marseille J Saba S Muyingo JG Khan, AIDS 20 907 914 10.1097/01.aids.0000218556.36661.47 16549976
28. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. ART-LINC ART-CC, Lancet 2006 367 817 824 10.1016/S0140-6736(06)68337-2 16530575